Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:12:18.152Z.
Consensus retrieved: 2026-10-06T12:00:57.920Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:12:18.152Z.
Quote observation: 2026-10-06T15:10:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c66db039e427230ae26789b54a30ba38da86a4a62527efc47f68a44edb52430
Forward PE Ratio (N/A) = Dated Quote Price ($10.22) / Consensus Forward EPS ($-1.48)
FORWARD PE RATIO
N/A
Monte Rosa Therapeutics, Inc.
Market Cap
$863.38M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $863.38M | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $883.79M | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.16M | N/A |
| Alumis Inc. (ALMS)vs › | $837.49M | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $837.26M | N/A |
| Bioventus Inc. (BVS)vs › | $892.39M | 16.91 |
| Jade Biosciences, Inc. (JBIO)vs › | $832.98M | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $899.78M | 6.16 |
| Ardelyx, Inc. (ARDX)vs › | $818.90M | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.43M | 42.41 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $10.22, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.48 | $-2.18 – $-0.49 | 6 | n/m |
| 2027-12-31 | $-1.97 | $-2.80 – $0.30 | 6 | n/m |
| 2028-12-31 | $-1.73 | $-3.00 – $0.91 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
